The search for new antimicrobials: Why we need new options

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 6, 2005, Pages 907-913

  Zinner, Stephen H ^a  

^a MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Community acquired methicillin resistant Staphylococcus aureus; Extended spectrum lactamase producing Gram negatives; Multidrug resistant Streptococcus pneumoniae; New treatment options; Polymicrobial infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFDITOREN PIVOXIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METICILLIN; MINOCYCLINE; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGACYL; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PENICILLIN RESISTANCE; PREDICTION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 28944450714     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.6.907     Document Type: Review

References (60)

1. Zinner SH, Wise R, Moellering RC Jr. Maximizing antimicrobial efficacy/minimizing antimicrobial resistance: a paradigm for the new millennium. Clin. Infect. Dis. 33(Suppl. 3) S107-S260 (2001).
2. Memish ZA, Venkatesh S, Shibl AM. Impact of travel on international spread of antimicrobial resistance. Int. J. Antimicrob. Agents 21, 135-142 (2003).
3. Duckro AN, Blom DW, Lyle EA et al. Transfer of vancomycin-resistant enterococci via healthcare worker hands. Arch. Intern. Med. 165, 302-307 (2005).
4. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7, 178-182 (2001).
5. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am. J. Med. 117(Suppl. 3A) S3-S15 (2004).
6. Shah AA, Hasan F, Ahmed S et al. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β-lactamases. Res. Microbiol. 155, 409-421 (2004).
7. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin. Infect. Dis. 39, 92-97 (2004).
8. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9, 1065-1078 (1987).
9. Linden PK. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. Am. J. Med. 104, S24-S33 (1998).
10. Jacobs MR, Johnson CE. Macrolide resistance: an increasing concern for treatment failure in children. Pediatr. Infect. Dis. J. 22 (8 Suppl) S131-S138 (2003).
11. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin. Infect. Dis. 35, 1505-1511 (2002).
12. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morb. Mortal. Wkly Rep. 53, 322-323 (2004).
13. Barber M. Methicillin resistant staphylococci. J. Clin. Pathol. 14, 385-393 (1961).
14. Panlilio AL, Culver DH, Gaynes RP et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect. Control Hosp. Epidemiol. 13, 582-586 (1992).
15. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32, 114-132 (2001).
16. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31, 481-498 (2003).
17. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9, 1415-1422 (2003).
18. Wong SS, Ng TK, Yam WC et al. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn. Microbiol. Infect. Dis. 36, 261-268 (2000).
19. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann. Intern. Med. 124, 329-334 (1996).
20. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352, 1436-1444 (2005).
21. Anonymous. Four pediatric deaths from commmunity acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. Morb. Mortal. Wkly Rep. 48, 707-710 (1999).
22. Kazakova SV, Hageman JC, Matava M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352, 468-475 (2005).
23. Steward CD, Raney PM, Morrell AK et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J. Clin. Microbiol. 43, 1716-1721 (2005).
24. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin. Infect. Dis. 39(Suppl. 3) S142-S150 (2004).
25. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38(Suppl. 4) S357-S362 (2004).
26. Ambrose P, Bast D, Doern GV et al. Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clin. Infect. Dis. 39, 1554-1556 (2004).
27. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin. Infect. Dis. 38(Suppl. 4) S322-S327 (2004).
28. Farrell DJ, Morrissey I, Bakker S et al. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48, 3169-3171 (2004).
29. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47, 1867-1874 (2003).
30. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health. 90, 223-229 (2000).
31. Metlay JP, Hofmann J, Cetron MS et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30, 520-528 (2000).
32. Fogarty C, Goldschmidt R, Bush K. Bacteraemic pneumonia due to multiresistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin. Infect. Dis. 31, 613-615 (2000).
33. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35, 556-564 (2002).
34. Jones ME, Draghi DC, Thornsberry C et al. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3, 14 (2004).
35. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48, 4574-4581 (2004).
36. Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J. Clin. Microbiol. 42, 1089-1094 (2004).
37. Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in nonhospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis. 23, 163-167 (2004).
38. Lautenbach E, Strom BL, Bilker WB et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin. Infect. Dis. 33, 1288-1294 (2001).
39. Falagas ME, Siakavella S. Bacteroides, Prevotella, and Porphyromonas species. A review of antibiotic resistance and therapeutic options. Int. J. Antimicrob. Agents 15, 1-9 (2000).
40. Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis Group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. 35(Suppl. 1) S126-S134 (2002).
41. Golan Y, McDermott LA, Jacobus NV, Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 52, 208-213 (2003).
42. Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. 9, 475-488 (2003).
43. Elsaghier AA, Brazier JS, James EA. Bacteraemia due to Bacteroides fragilis with reduced susceptibility to metronidazole. J. Antimicrob. Chemother. 51, 1436-1437 (2003).
44. Nguyen MH, Yu VL, Morris AJ et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30, 870-876 (2000).
45. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37, 997-1005 (2003).
46. Doern GV, Jones RN, Pfaller MA et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). SENTRY study group (North America). Diagn. Microbiol. Infect. Dis. 34, 65-72 (1999).
47. Lipsky BA. Medical treatment of diabetic foot infections. Clin. Infect. Dis. 39(Suppl. 2) S104-S114 (2004).
48. Combes A, Figliolini C, Trouillet JL et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 121, 1618-1623 (2002).
49. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 64, 1621-1642 (2004).
50. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am. J. Respir. Crit. Care Med. 153, 1711-1725 (1996).
51. Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36, 1418-1423 (2003).
52. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64, 63-88 (2004).
53. Pankey GA. Tigecycline. J. Antimicrob. Chemother. 56(3) 470-480 (2005).
54. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind Phase 3 comparison studies with vancomycin/aztreonam. Clin. Infect. Dis. (2005) (In press).
55. Babinchak T, Ellis-Gross E, Dartois N et al. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl 5) S354-S367 (2005)
56. Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development. Clin. Infect. Dis. 31, 1279-1286 (2004).
57. Guay DR. Dalbavancin: an investigational glycopeptide. Expert Rev. Anti Infect. Ther. 2, 845-852 (2004).
58. Mercier RC, Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti Infect. Ther. 3, 325-332 (2005).
59. Pace JL, Judice JK. Telavancin (Theravance). Curr. Opin. Investig. Drugs 6, 216-225 (2005).
60. Wise R. The relentless rise of resistance? J. Antimicrob. Chemother. 54, 306-310 (2004).